Diabetes Drugs May Lower Risk of Dementia and Parkinson’s, Study Finds

Summary: A new study suggests that a class of diabetes drugs called SGLT2 inhibitors may be associated with a reduced risk of developing dementia and Parkinson’s disease in people with type 2 diabetes.

Estimated reading time: 5 minutes

A recent study published in Neurology, the medical journal of the American Academy of Neurology, has revealed a potential link between a class of diabetes drugs and a lower risk of developing dementia and Parkinson’s disease. The research, focusing on sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, provides hope for those with type 2 diabetes who are at an increased risk of cognitive impairment.

The study, conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, examined the health records of 358,862 people with type 2 diabetes who started diabetes medication between 2014 and 2019. The findings suggest that SGLT2 inhibitors, which work by causing the kidneys to remove sugar from the body through urine, may offer protective benefits against neurodegenerative diseases.

Study Findings and Implications

The research team, led by Dr. Minyoung Lee, compared individuals taking SGLT2 inhibitors with those using other oral diabetes medications. After adjusting for various factors, including diabetes complications and other medications, the results were striking:

• A 20% reduced risk of Alzheimer’s disease for those taking SGLT2 inhibitors
• A 20% reduced risk of Parkinson’s disease
• A 30% reduced risk of developing vascular dementia

Dr. Lee commented on the significance of these findings: “We know that these neurodegenerative diseases like dementia and Parkinson’s disease are common and the number of cases is growing as the population ages, and people with diabetes are at increased risk of cognitive impairment, so it’s encouraging to see that this class of drugs may provide some protection against dementia and Parkinson’s disease.”

The incidence rates for various conditions among study participants were notable:

• Alzheimer’s disease: 39.7 cases per 10,000 person-years for SGLT2 inhibitor users, compared to 63.7 cases for those on other diabetes drugs
• Vascular dementia: 10.6 cases per 10,000 person-years for SGLT2 inhibitor users, versus 18.7 cases for the other group
• Parkinson’s disease: 9.3 cases per 10,000 person-years for SGLT2 inhibitor users, compared to 13.7 cases for those on other medications

Limitations and Future Research

While the results are promising, it’s important to note the study’s limitations. The average follow-up period was relatively short – two years for those taking SGLT2 inhibitors and four years for the comparison group. Dr. Lee acknowledged this limitation, stating, “It’s possible that some participants would later develop dementia or Parkinson’s disease.”

The researcher emphasized the need for further investigation: “The results are generally consistent even after adjusting for factors like blood pressure, glucose, cholesterol and kidney function. More research is needed to validate the long-term validity of these findings.”

This study’s implications could be far-reaching, potentially influencing treatment decisions for millions of people with type 2 diabetes. However, it’s crucial to remember that while the association between SGLT2 inhibitors and reduced neurodegenerative disease risk is significant, it does not prove causation. Additional long-term studies will be necessary to confirm these findings and explore the underlying mechanisms.

As the global population ages and the prevalence of both diabetes and neurodegenerative diseases increases, research like this becomes increasingly vital. It offers hope for new strategies to combat these challenging conditions and improve the quality of life for millions of people worldwide.

Quiz

1. What class of diabetes drugs did the study focus on?
2. By what percentage did SGLT2 inhibitors reduce the risk of vascular dementia?
3. What was the average age of participants in the study?

Answer Key:

1. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins
2. 30%
3. 58 years old

Further Reading:

1. American Academy of Neurology: https://www.aan.com/
2. Brain & Life Magazine: https://www.brainandlife.org/

Glossary of Terms:

1. SGLT2 inhibitors: A class of diabetes drugs that lower blood sugar by causing the kidneys to remove sugar from the body through urine.
2. Neurodegenerative diseases: Conditions characterized by the progressive loss of structure or function of neurons, including diseases like Alzheimer’s and Parkinson’s.
3. Vascular dementia: A type of dementia caused by problems with blood flow to the brain.
4. Incidence rate: The number of new cases of a disease occurring within a specific time period.
5. Person-years: A measurement that takes into account both the number of people in a study and the amount of time each person spends in the study.
6. Retrospective study: A type of research that looks back in time, using existing data to examine patterns or outcomes.

Enjoy this story? Get our newsletter! https://scienceblog.substack.com